NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Alpha Natural

(ANR)

was downgraded at Dahlman Rose from Buy to Hold. Company is leveraged to lower met coal pricing, Dahlman Rose said.

Peabody Energy

(BTU) - Get Report

was downgraded at Dahlman Rose from Buy to Hold. It will take time for coal demand to catch up with supply, Dahlman Rose said.

Conagra

(CAG) - Get Report

was upgraded at JP Morgan from Neutral to Overweight. Valuation call, based on a $29 price target, JP Morgan said.

CSX

(CSX) - Get Report

was downgraded at Dahlman Rose from Buy to Hold, Dahlman Rose said. Company is leveraged to lower coal volume and pricing, Dahlman Rose said.

General Mills

(GIS) - Get Report

was downgraded at JP Morgan from Overweight to Neutral. $40 price target. Company will likely take longer to fix its yogurt problems, JP Morgan said.

Gamestop

(GME) - Get Report

was upgraded at Goldman Sachs to Buy. $25 price target. Estimates were also boosted, as the company will likely buy back more stock, Goldman said.

Humana

(HUM) - Get Report

was upgraded at Leerink Swann from Market Perform to Outperform. Company can address margin issues in the coming quarters, Leerink Swann said.

Informatica

(INFA)

was upgraded at Baird from Neutral to Outperform. $40 price target. Majority of the company's challenges are fixable, Baird said.

Ingersoll-Rand

(IR) - Get Report

was downgraded at Bank of America/Merrill Lynch to Neutral. Valuation call, based on a $48 price target, BofA/Merrill said.

Manchester United

(MANU) - Get Report

was initiated with a Neutral rating at Nomura. $13 price target. Expect player costs to keep rising, Nomura said.

Manchester United was started with a Buy rating at Deutsche Bank. $17 price target. Expect solid revenue grew, driven by better team performance, Deutsche said.

Norfolk Southern

(NSC) - Get Report

was downgraded at Dahlman Rose from Buy to Hold. Met coal export prices are declining, Dahlman Rose said.

Northwestern

(NEW) - Get Report

was downgraded from Outperform to Neutral at Robert Baird said. Valuation call, based on a $38 price target, Baird said.

NYSE Euronext

(NYX)

was upgraded at Keefe, Bruyette & Woods from Market Perform to Outperform. Valuation call, based on a $29 price target, KBW said.

Tivo

(TIVO) - Get Report

was upgraded at JP Morgan from Neutral to Overweight. $13 price target. Company is at an inflection point, with potential catalysts ahead, JP Morgan said.

TST Recommends

Walter Energy

(WLT)

was downgraded at Dahlman Rose from Buy to Hold. Estimates also cut, given lower expected met coal prices, Dahlman Rose said.

STOCK COMMENTS / EPS CHANGES

Apple

(AAPL) - Get Report

estimates, target were increased at Wedbush. Estimates were raised through 2013. Expect an earlier iPhone 5 launch and mini iPad introduction in 2013, Wedbush said. Outperform rating and new $885 price target.

Autozone

(AZO) - Get Report

was cut from the Conviction Buy List at Goldman Sachs. $415 price target. Sector growth has been slowing, Goldman said. Buy rating.

Celgene

(CELG) - Get Report

price target was boosted at BMO Capital to $90. Revlimid patents should hold up well against generic challenges, BMO said. Outperform rating.

Greenhill

(GHL) - Get Report

estimates, target boosted at Credit Suisse. Shares are now seen reaching $48. Estimates were also increased, as the company is carrying a lot of momentum into the second half of the year, Credit Suisse said. Neutral rating.

Intel

(INTC) - Get Report

estimates, price target were cut at Credit Suisse. Shares are now seen reaching $32. Estimates were also reduced, given lower PC demand. Outperform rating.

Intuitive Surgical

(ISRG) - Get Report

numbers were cut at JMP Securities. Shares are now seen reaching $625. Estimates were also reduced, given weaker pricing, JMP said. Outperform rating.

Labcorp

(LH) - Get Report

estimates were raised at Piper Jaffray through 2013. Medtox acquisition should add to earnings, Piper said. Neutral rating and $91 price target.

Medivation

(MDVN)

numbers were raised at Jefferies. Shares are now seen reaching $122. Estimates were also raised on Xtandi approval, Jefferies said. Buy rating.

Medivation estimates, target raised at Credit Suisse. Shares are now seen reaching $149. Estimates were also increased, given the earlier-than-expected approval of Xtandi, Credit Suisse said. Outperform rating.

Ixia

(XXIA)

estimates, price target were raised at Lazard. Shares are now seen reaching $17. Estimates were also increased, following upbeat meetings with management, Lazard said. Buy rating.

Zimmer

(ZMH)

price target was boosted at Bank of America/Merrill Lynch. Shares are now seen reaching $72. Growth should accelerate in 2013, BofA/Merrill said. Buy rating.

>To submit a news tip, email:

tips@thestreet.com

.

READERS ALSO LIKE:

>>Is Intel Dead Money?

>>Where Is the Market Going? Nobody Knows

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

This article was written by a staff member of TheStreet.